Search | DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Displaying 1 result.

- Speech
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
Raghav, Kanwal Pratap Singh Siena, Salvatore Takashima, Atsuo Kato, Takeshi Van den Eynde, Marc[UCL] Di Bartolomeo, Maria Komatsu, Yoshito Kawakami, Hisato Peeters, Marc Andre, Thierry Lonardi, Sara Yamaguchi, Kensei Tie, Jeanne Gravalos Castro, Cristina Strickler, John H Barrios, Daniel Yan, Qi Kamio, Takahiro Kobayashi, Kojiro Yoshino, Takayuki (2023) American Society of ClinicalOncology (ASCO)2023 — McCormick Place, 2301 S King Dr, Chicago, IL 60616, USA